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ABSTRACT
Tumor lysis syndrome is a well-characterized and potentially deadly complication of spontaneous or treatment-related 
tumor destruction, and it is most commonly associated with hematologic malignancies. Our case illustrates a rare example 
of fatal tumor lysis syndrome in the setting of metastatic gastric adenocarcinoma treated with radiation therapy. This case 
highlights the critical importance of identifying patients with solid organ malignancies at risk for tumor lysis syndrome 
and of early recognition and treatment of this syndrome. 
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INTRODUCTION
Tumor lysis syndrome is a potentially fatal complication 
of spontaneous or treatment-related tumor destruction, 
and it has been well-characterized in hematologic 
malignancies. The following case illustrates a unique 
example of fatal tumor lysis syndrome occurring a solid 
organ malignancy setting in a patient with metastatic 
gastric adenocarcinoma treated with radiation therapy. 
To the authors’ knowledge, only 9 prior cases of tumor lysis 
syndrome have been reported in patients with metastatic 
gastric adenocarcinoma, and none of these occurred after 
radiation treatment alone (Table 1). This case highlights the 
critical importance of identifying patients with solid organ 
malignancies at risk for tumor lysis syndrome and of early 
recognition and treatment of this syndrome.
CASE REPORT
A 43-year-old male presented to the Emergency 
Department (ED) with new-onset lightheadedness when 
standing. He had never experienced similar episodes 
and denied syncope. He also complained of abdominal 
discomfort and bloating. Past medical history was 
significant for untreated hypertension, morbid obesity, 
and obstructive sleep apnea. He described losing 11,5 kg 
over the preceding 6 months attributable to lifestyle 
changes. He was not prescribed any medications. Family 
history was significant for coronary artery disease, 
hypertension, and colorectal cancer. Complete blood 
count (CBC) in the ED was significant for anemia 
(hemoglobin 8.6 g/dL, reference value [RV]: 13.7 - 
17.5 g/dL). The patient was discharged and instructed 
to follow up with his primary care physician to schedule 
an outpatient computed tomography (CT) scan.
Two days after discharge, he presented to the 
outpatient clinic with continued lightheadedness and 
increasing exercise intolerance. Physical examination 
revealed pale conjunctiva, tachycardia, and guaiac 
positive stool. Repeat CBC revealed worsening anemia 
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(hemoglobin 7.0 g/dL). Peripheral smear and iron 
studies were consistent with iron deficiency anemia. 
CT scan of the abdomen and positron emission 
tomography (PET) scan revealed thickening of the 
gastric cardia suspicious for malignancy along with 
multiple liver masses and adenopathy suspicious for 
metastatic disease (Figure 1).
Esophagogastroduodenoscopy (EGD) revealed 
a large, ulcerated mass extending from the gastric 
cardia into the distal esophagus. Biopsies of the 
mass were performed, showing poorly differentiated 
adenocarcinoma on histology.
Fluorescence in situ hybridization for HER2/
NEU amplification was negative. The patient was 
subsequently treated with 5 cycles of palliative x-ray 
radiation therapy (XRT) to the distal esophagus/gastric 
cardia (total radiation dose 2000 cGy).
Upon completing cycle 5 of XRT, the patient 
presented to the ED. He was found to have refractory 
anemia (hemoglobin 6.6 g/dL), melena, and acute 
kidney injury with elevated serum BUN (108 mg/dL, 
RV: 10 - 20 mg/dL), and serum creatinine (2.03 mg/dL, 
RV: 0.80 - 1.50 mg/dL). During admission, the patient 
developed multiple electrolyte abnormalities, including 
hyponatremia, hyperkalemia, hyperphosphatemia, 
hypocalcemia, and hyperuricemia, consistent with 
tumor lysis syndrome (Table 2).
Table 1. Characteristics of previously reported cases of TLS in gastric adenocarcinoma from the literature.
Authors
Clinical Presentation
Age Sex Metastases Treatment
Woo9 36 M Liver, lymph nodes None
Han10 38 M Liver, lymph nodes Cisplatin and Capecitabine
Vodopivec8 57 M Liver, sternum Oxaliplatin, Leucovorin, Floxuradine, Docetaxel
Kobayashi11 69 M Liver, lymph nodes S1 and Cisplatin
Goyal12 51 M Liver, lymph nodes, L4 vertebra, adrenal gland, rectum
None (Cisplatin, Docetaxel, 
5-fluorouracil 2 months prior)
Caravaca-Fontàn13 Unknown Unknown Unknown None
Sàlmon-Gonzàlez14 79 M Liver, lymph nodes None
Lingamaneni15 48 M Lymph node 5-fluorouracil, leucovorin, oxaliplatin
Chen16 62 M Peritoneum, lymph nodes None
Index case 43 M Liver, lung, lymph nodes X-ray Radiation Therapy
Figure 1. Skull base to mid-thigh PET-CT following 
IV injection of 18-fluoro-2-deoxyglucose (FDG) with 
standard uptake period A  coronal and B  sagittal views. 
Hypermetabolic thickening involving the lesser curvature 
of the stomach is observed, as well as numerous 
hypermetabolic hypodensities are throughout the liver 
and lymph nodes.





Sodium 120 mmol/L 135-145 mmol/L
Potassium 6 mmol/L 3.5-5 mmol/L
Phosphate 12.4 mg/dl 2.5-4.5 mg/dl
Calcium 8.1 mg/dl 8.5-10.5 mg/dl
Uric acid 21.4 mg/dl 3.5-8.5 mg/dl
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The patient’s kidney function continued to 
dec l ine with worsening lact ic  ac idos is ,  l i ver 
insufficiency, and coagulopathy with elevated 
INR (2.7, RV: 0.9 - 1.1) and elevated D-dimer 
(>20000 FEU ng/ml, RV: <200 FEU ng/ml). During this 
hospitalization, the patient continued to decompensate 
despite maximal therapy, and he subsequently expired.
AUTOPSY FINDINGS
Consent was obtained from next of kin for a 
limited autopsy to investigate the thorax, abdomen, 
and pelvis. External examination revealed anasarca and 
was otherwise unremarkable. The abdominal cavity 
contained 1800 mL of serosanguinous ascitic fluid, 
and the stomach contained 1100 ml of clotted blood. 
A 5.5 x 6.0 x 0.9 cm solid mass was present within the 
gastric cardia with extension into the gastroesophageal 
junction. The segment of the esophagus distal to the 
tumor exhibited mucosal hyperemia, consistent with 
radiation esophagitis. Sections of the gastric tumor 
revealed poorly differentiated adenocarcinoma with 
signet ring features and extensive necrosis (Figure 2).
By immunohistochemistry, the tumor was positive 
for cytokeratin 7 (Bond, PA0138, pre-diluted), 
cytokeratin 20 (Leica, NCL-L-CK20, 1:50 dilution) and 
also showed weak CDX-2 (Cell Marque, EPR27644, 
1:100 dilution) positivity.
The lungs were involved by bilateral pleural based 
metastatic deposits of poorly differentiated adenocarcinoma 
(Figure 3) measuring up to 0.9 x 0.3 cm. The tumors in 
the lungs were strongly positive for CK20 and CK7, and 
weakly positive for CDX-2 by immunohistochemistry. 
Staining for TTF-1 (Biogenex, MU397, 1:20 dilution) was 
negative, and there was an extensive lymphovascular 
invasion, supporting metastasis.
The liver was grossly nodular and extensively 
involved by metastat ic,  poorly-differentiated 
adenocarcinoma, morphologically consistent with 
the gastric primary (Figure 4).
Figure 2. Photomicrographs of the gastric tissue showing A and D  poorly differentiated adenocarcinoma involving 
the gastric cardia (H&E, 100x, 200x respectively), B  strongly positive immunohistochemical staining for CK7 (100X) 
and C  CK20 (100X).
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Peri-pancreatic, mesenteric, perigastric, and 
gastrohepatic lymph node involvement by poorly 
differentiated gastric adenocarcinoma was present. 
The kidneys were edematous with smooth subcapsular 
surfaces grossly. Microscopic examination of the 
kidneys was limited by extensive autolysis, though 
hypertensive vasculopathy was apparent. The heart 
was grossly enlarged with left ventricular hypertrophy 
but without significant coronary artery atherosclerosis. 
Histologically, the heart showed myocyte hypertrophy 
without evidence of acute or chronic ischemic damage.
DISCUSSION
The laboratory and clinical definition of tumor lysis 
syndrome (TLS) is the development of hyperkalemia, 
hyperuricemia, hyperphosphatemia, and hypercalcemia 
with clinically significant sequelae such as acute kidney 
injury or cardiac dysrhythmia.1-6 Our patient presented 
with all of these metabolic disturbances by laboratory 
analysis and had clinical sequelae, including metabolic 
acidosis, renal, and hepatic failure. TLS can be a life-
threatening emergency due to the severity of these end-
organ effects and resulting in metabolic derangement. 
TLS can occur spontaneously or following treatment 
and is secondary to a large volume of tumor cells lysing 
with their components, subsequently being released 
into the bloodstream. It is well-described in the context 
of hematologic malignancies but is seen significantly 
less often in solid organ malignancy.1-8 Cases of 
TLS in patients with solid organ malignancies have 
been described as occurring sporadically, post-
Figure 3. Photomicrographs of the lung tissue showing- A  differentiated carcinoma (H&E, 200X), B strongly 
positive immunohistochemical staining for CK7 (200X), and C  CK20 (200X).
Figure 4. Gross autopsy photograph of the liver A showing diffuse involvement by rubbery tan-yellow nodular 
metastases with focal areas of necrosis; B  Micrograph of liver showing diffuse involvement by poorly differentiated 
carcinoma (H&E, 100x). 
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chemotherapy and post-radiotherapy, such as 
the case in our patient.1-6 Though cases of TLS in 
solid organ malignancies remain uncommon in the 
literature, they have occurred in many different primary 
sites.1,2,7,8 A literature review using combinations 
of keywords including “tumor lysis,” “tumor lysis 
syndrome,” “gastric adenocarcinoma,” and “gastric 
cancer” was performed utilizing PubMed, Scopus, 
Google Scholar and Web of Science. To the authors’ 
knowledge, there have been 9 previously reported 
cases of gastric adenocarcinoma with TLS (Table 1). 
In these cases, TLS occurred both spontaneously 
and secondary to chemotherapy. To our knowledge, 
the present case is the first reported case of TLS in 
gastric adenocarcinoma after only radiation therapy 
administration in the absence of chemotherapy.
In solid organ malignancies, risk factors for the 
development of TLS include high tumor burden and 
tumors with high proliferative/turnover rates, sometimes 
demonstrated by elevated lactate dehydrogenase 
(LDH).1-5 Intense initial treatment of tumor and high 
tumor sensitivity to treatment also increases the risk 
of TLS.3 Solid organ or hematologic malignancies with 
widely metastatic disease may have a larger tumor 
burden than the localized disease, which was the case 
in our patient who had a large primary gastric tumor 
as well as extensive nodal and hepatic metastases. 
Patients with dehydration, underlying kidney disease, 
hypotension or concurrent treatment with nephrotoxic 
agents are also at higher risk for TLS.3,8 Treatments 
depend on a patient’s specific electrolyte disturbance 
profile (calcium for hypocalcemia, potentially dialysis 
for severe hyperkalemia or hyperphosphatemia), but 
generally include supportive therapy such as aggressive 
fluid resuscitation, and treatment with allopurinol or 
rasburicase to decrease the formation and increase 
excretion of uric acid, respectively.2,3 Our patient 
received radiation therapy on an outpatient basis, 
subsequently presented to the ED with findings classic 
for TLS, and unfortunately had a fatal outcome.
CONCLUSIONS
This case is unique in highlighting an unusual 
consequence of a metastatic gastrointestinal malignancy 
culminating in fatal tumor lysis syndrome after 
outpatient radiation therapy. This case accentuates 
the importance of early recognition of TLS or pre-
emptively identifying at-risk patients with solid organ 
malignancies. This includes patients with high overall 
tumor burden including metastatic deposits or tumors 
with high proliferative rates, patients with tumors 
expected to be highly sensitive to treatment, and 
patients with underlying risk factors such as chronic 
kidney disease or hypovolemia. It is especially important 
for providers to give patients thorough instructions on 
potential signs of TLS, such as decreased urine output, 
muscle cramps, or mental changes. Providers should 
be cognizant that patients, such as ours, who may be 
undergoing treatment on an outpatient basis for solid 
organ malignancy, may not be receiving concurrent 
aggressive fluid resuscitation with treatment. As we 
continue to develop more efficacious treatments for 
aggressive malignancies, we must be acutely aware 
of the potential for TLS in patients with solid organ 
cancers.
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